VIVUS Inc (VVUS.O) Quote| Reuters.com
Edition:
United States

VIVUS Inc (VVUS.O)

VVUS.O on Nasdaq

1.10USD
24 Jun 2016
Change (% chg)

-- (+0.00%)
Prev Close
$1.10
Open
$1.05
Day's High
$1.12
Day's Low
$1.02
Volume
11,011,551
Avg. Vol
956,300
52-wk High
$2.61
52-wk Low
$0.92

VVUS.O

Chart for VVUS.O

About

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $114.50
Shares Outstanding(Mil.): 104.09
Dividend: --
Yield (%): --

Financials

  VVUS.O Industry Sector
P/E (TTM): -- 32.69 34.11
EPS (TTM): -0.87 -- --
ROI: -35.86 15.00 14.23
ROE: -364.58 16.08 15.46

BRIEF-Vivus receives notice from Hetero USA that it has filed with U.S. FDA ANDA for generic versions of all strengths of Stendra tablets

* Received notice from Hetero USA that it has filed with U.S. FDA ANDA for generic versions of all strengths of Stendra tablets

Jun 21 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00
Provider : Stock Traders Daily
$20.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.